Galena Biopharma Inc (NASDAQ:GALE) announced that data from the Company’s Phase 1 study with GALE-301, or Folate Binding Protein (FBP), was presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting. Galena Biopharma Inc (NASDAQ:GALE) weekly performance is 20.18%. On last trading day company shares ended up $2.68. Analysts mean target price for the company is $6.88. Galena Biopharma Inc (NASDAQ:GALE) distance from 50-day simple moving average (SMA50) is 17.73%.
Amkor Technology, Inc. (NASDAQ:AMKR) reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.03 by $0.06. The company had revenue of $696.00 million for the quarter, compared to the consensus estimate of $678.13 million. During the same quarter in the prior year, the company posted $0.07 earnings per share. The company’s quarterly revenue was up 1.2% on a year-over-year basis. Analysts expect that Amkor Technology will post $0.70 EPS for the current fiscal year. Amkor Technology, Inc. (NASDAQ:AMKR) shares advanced 5.12% in last trading session and ended the day on $11.30. AMKR Gross Margin is 19.00% and its return on assets is 3.70%. Amkor Technology, Inc. (NASDAQ:AMKR) quarterly performance is 85.25%.
On 2 JUNE Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Varlilumab is an immunotherapy designed to enhance the body’s natural immune response by directly activating T cells that can specifically recognize and kill cancer cells. Preclinical data support the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Varlilumab will enter at least four combination studies in the second half of 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved up 7.40% in last trading session and was closed at $16.26, while trading in range of $15.04 – $16.99. Celldex Therapeutics, Inc. (NASDAQ:CLDX) year to date (YTD) performance is -32.84%.
On 6 JUNE Exelixis, Inc. (NASDAQ:EXEL) has recently reported that it would attend a few important investor conferences at which a member of the company would be giving a presentation regarding the plans of the company for achieving long-term growth and progress. Exelixis, Inc. (NASDAQ:EXEL) ended the last trading day at $3.51. Company weekly volatility is calculated as 3.63% and price to cash ratio as 2.68. Exelixis, Inc. (NASDAQ:EXEL) showed a positive weekly performance of 7.67%.
CytRx Corporation (NASDAQ:CYTR) said it is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx Corporation (NASDAQ:CYTR) has completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for soft tissue sarcomas, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx Corporation (NASDAQ:CYTR) weekly performance is 17.87%. On last trading day company shares ended up $4.75. Analysts mean target price for the company is $11.00.CytRx Corporation (NASDAQ:CYTR) distance from 50-day simple moving average (SMA50) is 36.73%.
Leave a Reply